tbuckley/cabot-search huggingface dataset:
Polypharmacy in elders with cancer: An analysis of the Ohio medicaid population
Authors: S. M. Koroukian, C. Owusu, E. Madigan, M. Diaz
Journal: Journal of Clinical Oncology (2007)

19550 Background: Polypharmacy in the elderly complicates therapy, increases cost of treatment and is a challenge to healthcare agencies. However, the impact of polypharmacy on the care of the older cancer patient has been poorly described. The objective of this study was to characterize the use of pharmacy drugs in the month preceding cancer diagnosis among Ohio Medicaid beneficiaries 65 years of age or older, and diagnosed with incident breast, prostate, or colorectal cancer during the study period 1997–2001. Methods: Medicaid beneficiaries were identified by linking data from the Ohio Cancer Incidence Surveillance System (OCISS) with Medicaid enrollment and claims files on a year-by-year basis. Because of potentially incomplete claims history, the study was limited to patients who were enrolled in Medicaid continuously in the year preceding initial cancer diagnosis. Additionally, those with spenddown or nursing home stay in that time frame were excluded from the analysis. Demographics, anatomic cancer site and stage were retrieved from the OCISS, and all non-pharmacy claims for services received in the year prior to cancer diagnosis were accounted for in deriving the Charlson comorbidity score. Results: The study population included 652 patients: 282 with incident breast cancer, 111 with prostate cancer, and 259 with colorectal cancer. The median age was 73, 74, and 75 years among breast, prostate, and colorectal cancer patients, respectively. Nearly 45% were prescribed at least one type of medication in the month preceding cancer diagnosis. Of those with any prescription in that time period, nearly 49% were prescribed 5 or more types of medications. The most commonly prescribed types of medication were narcotic analgesics, diuretics and potassium replacement, anti- hypertensive agents, laxatives, antianxiety drugs, and antidpressants. No significant variations in the use of medications were observed across the different subgroups of the study population. Conclusions: Polpypharmacy (5 or more types of medication) was present in more than 22% of patients in this study population. The effects of polpypharmacy above and beyond that of comorbidities, disability, and other geriatric syndromes, relative to cancer-related outcomes should be determined. No significant financial relationships to disclose.
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
Authors: J. Herrstedt, J. Huober, F. Priou, H. Müller, M. Baekelandt, C. Kurzeder, J. Pfisterer, A. Stähle, I. Ray-Coquard, A. du Bois
Journal: Journal of Clinical Oncology (2009)

LBA5510 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Linking dispositional mindfulness and positive psychological processes in cancer survivorship: A multivariate path analysis.
Authors: Anna Catherine Beck, Eric Garland, Paul Thielking, Shelley White
Journal: Journal of Clinical Oncology (2014)

237 Background: Research indicates dispositional mindfulness is linked with positive psychological outcomes. This disposition, which is malleable through training, is characterized by the tendency exhibit nonjudgmental and nonreactive awareness of one’s thoughts, emotions, and present moment sensory-perceptual experience. Although this trait has been linked with salutary outcomes in the broader mental health literature, less is known about the trait of mindfulness in cancer survivors and how it may be linked with indices of psychological and physical health relevant to cancer survivorship. Methods: We conducted a multivariate path analysis of cross-sectional data from a heterogenous sample of cancer patients (N = 97) to test a conceptual model linking dispositional mindfulness with cancer-related quality of life via positive psychological processes. Results: We found that patients with higher levels of dispositional mindfulness were more likely to pay attention to positive experiences (β = 0.47), a propensity which was associated with positive reappraisal of stressful life events (β = 0.46). Patients who endorsed more frequent positive reappraisal had a greater sense of sense of meaning in life (β = 0.43) and savored rewarding or life affirming events (β = 0.45). In turn, those who engaged in high levels of savoring had better quality of life (β = 0.33) and suffered from less emotional distress (β = -0.54). Overall model fit was excellent, χ 2 /df= 1.18; CFI = 0.99; RMSEA = 0.04 (0.00, 0.12). Conclusions: The data support our hypothetical model of the processes by which mindfulness promotes psychological flourishing in the face of cancer. Dispositional mindfulness appears to broaden attention from a myopic focus on illness to encompass previously unattended positive features of the social and natural environment. With this broader set of information from which new, more adaptive situational appraisals may be generated, mindfulness may engender positive reappraisals of stressful life events and promote sense of meaning in life. When sustained over time, these processes may propel an upward spiral of positive cognition-emotion interactions with salutary consequences for cancer survivorship.
Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases
Authors: B. Oyan, G. Tekuzman, I. Barista, A. Kars, A. Turker, Y. Ozisik, N. Guler, E. Baltali, S. Yalcin, I. Gullu
Journal: Journal of Clinical Oncology (2004)

6725
Homooligomerization of the ABC-transporter 3 and its functional significance
Authors: Sabrina Frixel, Eva Kaltenborn, Amelie S. Lotz-Havla, Søren W. Gersting, Ralf Zarbock, Matthias Griese
Journal: European Respiratory Journal (2014)

Background and aim: ABCA3 is a surfactant lipid transporter in the limiting membrane of lamellar bodies in alveolar type II cells. Mutations in the  ABCA3  gene cause respiratory distress syndrome in newborns and chronic interstitial lung disease in children and adults. ABCA3 belongs to the class of full ABC-transporters, which are supposed to be functional in their monomeric forms. Though other family members e.g. ABCA1 and ABCC7 have been shown to function as oligomers, the oligomerization state of ABCA3 remains to be elucidated.  Methods: Oligomerization of ABCA3 was investigated in cell lysates and crude membrane preparations from transiently and stably transfected HEK293 cells using blue native PAGE (BN-PAGE), gel filtration and co-immunoprecipitation. Additionally, homooliomerization was examined  in vivo  in cells using bioluminescence resonance energy transfer (BRET).  Results: Using BN-PAGE and gel filtration, methods that separate proteins in their native state according to their molecular size, we could show that non-denatured ABCA3 exists in different oligomeric forms, such as monomers, dimers, tetramers and even higher oligomers. Homooligomerization of ABCA3-wildtype was shown via co-immunoprecipitation of HA- and YFP-tagged ABCA3. Oligomerization could be verified  in vivo  by detecting positive interactions using BRET.  Conclusion: Besides its monomeric state, ABCA3 was detected in additional oligomeric forms. We therefore suggest transporter oligomerization as a central mechanism for ABCA3 function. Insights into the fundamentals of the transport process will provide a better understanding of ABCA3-related diseases and enable the analysis of patient mutations and its interactions.
Impact of Clinical Practice Guideline'S on Medical Practice and Survival for Head and Neck Cancer Management in Fisrt Line Treatment (N = 1121 Patients)
Authors: L. Tassy, P. Zrounba, D. Girodet, P. Ceruse, X. Pivot, M. Poupart, E. Villanueva, J. Pignat, E. Reyt, G. De Laroche, J. Prades, J. Fayette, D. Cellier, A. Lurkin, B. Laure, I.L. Ray-Coquard
Journal: Annals of Oncology (2014)
Phase II study of paclitaxel, tegafur/uracil and folinic acid as first line treatment in metastatic or recurrent head and neck squamous cell carcinomas
Authors: A. Berrocal, M. Pastor, C. Caballero, A. Segura, S. Garcera, A. Oltra, E. Nogueron, A. Blasco, P. Lopez, C. Camps
Journal: Journal of Clinical Oncology (2004)

5581 Background: Cisplatin alone or in combination remains the standard for recurrent/metastatic head and neck carcinoma, however it is associated with significant toxicity. Better toxicity profile could be observed with taxanes in this setting. Methods: Recurrent and/or metastatic squamous head and neck carcinoma patients not previously chemotherapy treated. No age limitation initially. Paclitaxel 175 mg/m2 day 1, tegafur/uracil 400 mg/m2 days 1 to 14, and folinic acid 90 mg days 1 to 14. Beta-tubulin mutations were evaluated to assess its relation with paclitaxel sensitivity. Results: 29 patients. Male/female 26/3, median age 59 (49–80) years. Primary tumours localizations were larinx / paranasal sinus / oral cavity / oropharinx / hipopharinx / others 12/1/4/4/2/6. Surgery in 69%, radiotherapy in 62%. Presentation was locoregional relapse in 10 (34.5%), locoregional and metastatic relapse in 10 and initially metastatic in 9 (31%). In 26 evaluated patients best responses have been complete response in 2 (8%), partial response in 3 (12%), stable disease in 3 and progression in 17 (68%). Median survival has been 27 weeks (95% CI: 18–35). Toxicity was found to be age dependent with 3 toxic deaths at the beginning of the trial all in old patients, so age was limited to 70 years without more toxic deaths. A total of 82 (median 3 (1–9)) courses were administered, hematologic toxicity was mild and present in 12 courses with grade I-II anaemia in 3, grade I-II leucopenia in 4, and grade I-II trombocytopenia in 3. Grade III-IV leucopenia occurred in 4 courses. Non hematologic toxicity per courses was, nausea and vomiting grade II in 14, grade II sensory neurophaty in 6, grade II-III mucositis in 8 and asthenia in 8. No relation between beta-tubulin mutations and response has been seen in the first 10 patients. Updated results will be presented Conclusions: moderately active combination. Toxicity is age dependent and moderate when older patients are excluded. Beta-tubulin mutation probably have no role in predicting response to paclitaxel No significant financial relationships to disclose.
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
Authors: U. Pelzer, K. Kubica, J. Stieler, I. Schwaner, G. Heil, M. Görner, M. Mölle, A. Hilbig, B. Dörken, H. Riess, H. Oettle
Journal: Journal of Clinical Oncology (2008)

4508 Background: For nearly ten years gemcitabine (G) was standard first line therapy for patients (pts) with advanced pancreatic cancer (APC). There is no consensus about second line therapy after disease progression while receiving G, but 5-FU-based regimens are considered. Randomized second line studies in APC are very rare. Our phase II study (ASCO 2002) showed activity of the OFF (oxaliplatin/folinic acid (FA)/5-Fluorouracil (FU) [24h] ) regimen in 23 pts. To examine the impact and the side effects of oxaliplatin we initiated a multicenter phase III study to compare OFF and FF in pts with G refractory APC. Methods: Pts with CT/ MRT confirmed PD on G in first line therapy, Karnofsky Performance Status (KPS) >60%, controlled pain, adequate hematological, renal and liver functions were eligible. Pts were stratified according to duration of first line therapy, KPS and tumor stage. We planned to randomized 165 pts to outpatient treatment with FF (5-FU 2g/m² (24h)/ FA 200 mg/m² (30min) on d1, d8, d15 and d22) or OFF (FF+oxaliplatin 85mg/m², d8, d22). In both arms the next cycle started on day 43. Pts were followed with regular staging at least every 3 months or at any signs of disease progression. Results: We recruited 168 pts between 02/2004 and 06/2007. Drop out rate is 4.8%. There is a full data assessment of 160 pts. Conclusions: We are able to present final results (side effects, progression free survival, overall survival) with an one year surveillance after study closure at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology, Pfizer Oncology, sanofi-aventis, GlaxoSmithKline, Amgen, Hoffman-La Roche
Bioelectrical impedance phase angle as a nutritional indicator in advanced breast cancer
Authors: D. Gupta, C. A. Lammersfeld, P. G. Vashi, S. L. Dahlk, J. L. Burrows, G. Lambert, J. F. Grutsch, C. G. Lis
Journal: Journal of Clinical Oncology (2005)

856 Background: Malnutrition is a strong predictor of morbidity and mortality in advanced cancer. Accurate assessment of malnutrition is a significant challenge in cancer patients. Bioelectrical impedance analysis (BIA) is a safe, simple, non-invasive and objective technique that is increasingly being used to evaluate nutritional status and changes in body composition in cancer. BIA measures resistance and reactance to the flow of a constant alternating electric current to a living organism, which in turn is used to calculate phase angle, a measure of cellular health and integrity. We investigated if BIA-derived phase angle could assess nutritional status as measured by Subjective Global Assessment (SGA) in advanced breast cancer. Methods: We evaluated a case series of 79 histologically confirmed stage III-IV breast cancer patients treated at Cancer Treatment Centers of America at Midwestern Regional Medical Center between January 2000 and July 2003. A Kruskal-Wallis (KW) test - owing to nonnormal distribution of phase angle - was conducted to evaluate differences in the median phase angle scores among the 3 SGA categories (well nourished, moderately malnourished, and severely malnourished). The correlation between phase angle and SGA was studied using Spearman’s rho (rho) correlation coefficient. Results: We found a modest but statistically significant negative correlation between phase angle and SGA (rho = -0.24; p = 0.032); the higher the phase angle, the lower the SGA, suggesting better nutritional status. The median phase angle scores for well-nourished (n = 49), moderately malnourished (n = 19), and severely malnourished (n = 11) patients were 5.97, 5.52, and 5.26 respectively. KW test was marginally significant,χ2 (2, N = 79) = 5.2, p = 0.07. It was interesting to see that some patients classified as well-nourished by the SGA had phase angle scores as low as 3.6, while some identified as severely malnourished had phase angle scores as high as 7.1. Conclusions: Our study demonstrates that BIA-derived phase angle could be a useful nutritional indicator in advanced breast cancer, however, further studies should focus on more extensive validation of this technique in cancer treatment settings. No significant financial relationships to disclose.
TeleObs: Bench test evaluation of a telemonitoring device for CPAP treatment
Authors: Ubiratan Freitas, Jérôme Desseaux, Olivier Thuillart, Ludivine Leseux, Jean Louis Fraysse
Journal: European Respiratory Journal (2014)

Introduction: Patients with moderate to severe forms of sleep apnea syndrome (SAS) are treated with a continuous positive airway pressure (CPAP). Daily use to CPAP treatment appears as a key factor to improve patients' health status. In France, since October 2013, patients newly treated by CPAP have to be equipped with a telemonitoring device remotely evaluates patient's treatment duration on a daily basis. That's why SADIR developed the TeleObs®. The aim of this study was to evaluate TeleObs® in a bench test: its possible impact to the CPAP treatment and its accuracy in measuring treatment duration and Apnea Hypopnea Index (AHI). Methods: All tests were made using the active test lung ASL 5000 (IngMar Medical, USA). Seven currently used CPAP treatment devices were tested with sessions' duration between 3 to 8 hours and AHI varying between 0.33 and 30 events per hour. Measured values sent from a communicating module were read from a certified telemedicine server, H2AD, located in France via a web interface. Preliminary results: The impact of the TeleObs® sensor on the CPAP treatment was found to be negligible. The maximal observed pressure drop was 0.18 cmH2O. The difference between the treatment duration measured by the device and actual values was 17 seconds in average [-0.5 sec; +8.8 min]. The difference between actual AHI and TeleObs® measured values was 0.55 in average [0; 3.8]. Conclusion: TeleObs® proved to be an accurate tool for monitoring CPAP use. It correctly measures critical parameters to evaluate the patients' adherence and effectiveness of the treatment. Plus, no major impact of installing TeleObs® in the respiratory circuit was noticed in any of the CPAP models tested.
Abstract P246: Lean Body Mass, Percent Body Fat, and HbA1c in the U.S. Population: The National Health and Nutrition Examination Survey (NHANES 1999-2006)
Authors: Julie K Bower, Rachel Brackett, Meredith C Foster, Randi E Foraker
Journal: Circulation (2015)

Introduction: Weight loss is an important component of diabetes prevention and management because of the known effect of adiposity on insulin resistance. While both muscle (lean mass) and fat mass are known to serve important metabolic functions, most studies of obesity and diabetes use proxy measures for overall or abdominal obesity without accounting for the composition of that mass. The aim of this study was to examine the association of total and trunk lean body mass and fat mass with hemoglobin A1c (HbA1c) - an indicator of glucose control in persons with diabetes and a risk marker in non-diabetic populations - in the general U.S. population. Methods: We conducted a cross-sectional analysis of data from the NHANES collected in 1999-2006 in participants aged 18-69 years. Lean body mass and percent body fat were determined using dual energy x-ray absorptiometry (DXA); analyses were weighted and multiple imputation was applied to account for missing DXA data. Associations of body composition with HbA1C were evaluated using multiple linear regression. Results: The study sample included 1,085 participants with diagnosed diabetes (mean age 56 years, 50% male, mean HbA1c=7.6%) and 15,597 participants without diabetes (mean age 40 years, 51% women, mean HbA1c=5.3%). Trunk lean mass and total lean mass were significantly associated with lower HbA1c in adults without diabetes, independent of body mass index (BMI) and waist circumference. After adjustment for age, sex, race/ethnicity, and waist circumference, each 10 kg increase in trunk lean mass was associated with 0.07-% points lower HbA1c (95% CI: -0.09, -0.03). After adjustment for age, sex, race/ethnicity, and BMI, each 10kg increase in total lean mass was associated with 0.03-% points lower HbA1c (95% CI: -0.05, -0.0). Each 5% increase in trunk fat was associated with 0.5-% point higher HbA1c (95% CI: 0.45, 0.55) and each 5% increase in total fat was associated with 0.05-% point higher HbA1c (95% CI: 0.05, 0.06). Lean mass and percent body fat were not associated with HbA1c in participants with diagnosed diabetes (p &gt; 0.05). Conclusions: Lean mass is independently associated with HbA1c in adults without diabetes. Interventions that target both weight loss where warranted and increasing lean mass via resistance training may have the most beneficial impact for diabetes prevention.
The Histochemical Distribution of Protein-Bound Sulfhydryl Groups&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Russell J. Barrnett, M.D.
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article The Histochemical Distribution of Protein-Bound Sulfhydryl Groups Get access Russell J. Barrnett, M.D. Russell J. Barrnett, M.D. Department of Anatomy, Harvard Medical School, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 4, February 1953, Pages 905–925, https://doi.org/10.1093/jnci/13.4.905 Published: 01 February 1953 Article history Received: 06 October 1952 Published: 01 February 1953
Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC).
Authors: J. Ho, S. Gill, R. Woods, H. F. Kennecke
Journal: Journal of Clinical Oncology (2010)

3624 Background: The incidence of capecitabine-associated dose-limiting toxicities (DLT) is higher in clinical practice than reported in trials (ASCO 2008, abstr 4101). This often results in a reduced relative dose intensity (RDI). We examined the pattern and impact of DLT and RDI on relapse-free (RFS) and overall survival (OS) in patients (pts) receiving adjuvant capecitabine for CRC. Methods: A chart review was conducted on pts treated at the BC Cancer Agency with ≥1 cycle of single-agent capecitabine for stage II/III CRC. The reference capecitabine regimen was based on 8 cycles dosed at 1,250 mg/m2 BID. RFS and OS were analyzed by the Kaplan-Meier method and multivariate Cox proportional-hazards models. Results: 179 pts (median age 69y, 56% male, 90% colon, 73% stage III) were included. 85% of pts experienced at least one episode of DLT, with the most common causes being HFS (54%) and diarrhea (19%). Median RDI was 70% with 69% of pts having an RDI of <80%. Receiving less than the median RDI was associated with performance status ≥2 (17% vs. 3%, p=0.0016) and having ≥1 DLT (78% vs. 59%, p=0.010). On univariate analysis, pts receiving greater than the median RDI had significantly better RFS (3y 69% vs. 32%, p=0.03) and OS (3y 62% vs. 22%, p=0.01). On multivariate analysis, RDI remained an independent predictor for RFS (HR 0.35, 0.14-0.88) and OS (HR 0.37, 0.17-0.82) when controlled for age, nodal status and gender (see Table). Conclusions: In clinical practice, DLTs from adjuvant capecitabine monotherapy are not uncommon and can lead to reduced RDI. In our retrospective study, achieving an RDI of >70% was independently associated with RFS and OS. However, this was achieved in only 50% of the cohort. Strategies to optimize toxicity management while maintaining dose intensity should be considered for patients on AT with oral capecitabine. Multivariate model for OS Variable HR 95% CI P value RDI (>70%) 0.35 0.14-0.88 0.026 Node status (+ve vs. –ve) 4.47 1.01-19.71 0.048 Sex (M vs. F) 2.85 1.13-7.16 0.026 Age (per year) 0.96 0.92-0.99 0.022 Multivariate model for RFS Variable HR 95% CI P value RDI (>70%) 0.37 0.17-0.82 0.014 Nodal status (+ve vs –ve) 3.3502 1.10-10.20 0.033 Age (per year) 0.95 0.91-0.99 0.032 No significant financial relationships to disclose.